GIPR and growth hormone secreting pituitary adenoma 1: Introducing targeted therapy to antagonize the GIPR on GIPR-expressing somatotroph adenomas could represent a novel treatment approach for acromegaly patients with a paradoxical GH response pattern to OGTT [46].